These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6235326)

  • 1. A trial of autologous plasma perfusion over protein A in patients with breast cancer.
    Fer MF; Beman J; Stevenson HC; Maluish A; Moratz C; Delawter T; Foon K; Herberman RB; Oldham RK; Terman DS
    J Biol Response Mod; 1984; 3(3):352-8. PubMed ID: 6235326
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultrastructural changes in breast tumors of patients following treatment with plasma perfused over immobilized protein A.
    Daskal Y; Mattioli CA; Terman DS
    J Biol Response Mod; 1984; 3(3):247-54. PubMed ID: 6379108
    [No Abstract]   [Full Text] [Related]  

  • 3. Staphylococcal protein A immunoadsorptive column induces mitogenicity in perfused plasma.
    Bertram JH; Hengst JC; Mitchell MS
    J Biol Response Mod; 1984; 3(3):235-40. PubMed ID: 6379107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial of plasma perfusion over immobilized staphylococcal protein A in metastatic breast cancer.
    Ventura GJ; Buzdar AU; Kau S; Lichtiger B; Hortobagyi GN
    Cancer Treat Rep; 1987 Apr; 71(4):411-3. PubMed ID: 3548958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quantitative and functional response of a lymphatic subpopulation during adjuvant intermittent chemo-immunotherapy in breast cancer].
    Betzler M; Flad HD; Huget R; Schreml W; Schlag P; Herfarth C
    Chir Forum Exp Klin Forsch; 1978; (1978):227-30. PubMed ID: 313321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with Staphylococcus aureus and protein A in the treatment of canine malignancies.
    Bowles CA; Messerschmidt G; Deisseroth AB
    J Biol Response Mod; 1984; 3(3):260-5. PubMed ID: 6379110
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
    Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
    Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
    Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
    Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical response to protein a-treated plasma infusions and in vitro correlation.
    MacKintosh FR; Bennett K; Hall SW
    J Biol Response Mod; 1984; 3(3):336-40. PubMed ID: 6379117
    [No Abstract]   [Full Text] [Related]  

  • 10. Does perfusion with treated plasma cure cancer?
    Hellström KE; Hellström I
    N Engl J Med; 1981 Nov; 305(20):1215-6. PubMed ID: 6270555
    [No Abstract]   [Full Text] [Related]  

  • 11. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
    Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
    Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
    Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
    Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials with Staphylococcus aureus and protein A in the treatment of malignant disease.
    Messerschmidt GL; Bowles CA; Henry DH; Deisseroth AB
    J Biol Response Mod; 1984; 3(3):325-9. PubMed ID: 6379115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
    Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
    Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staphylococcal protein A in neoplastic disease.
    Terman DS
    J Biol Response Mod; 1984; 3(3):316-24. PubMed ID: 6379114
    [No Abstract]   [Full Text] [Related]  

  • 18. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
    Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses to guided imagery during breast cancer treatment.
    Lengacher CA; Bennett MP; Gonzalez L; Gilvary D; Cox CE; Cantor A; Jacobsen PB; Yang C; Djeu J
    Biol Res Nurs; 2008 Jan; 9(3):205-14. PubMed ID: 18077773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function.
    Chen W; Chan AS; Dawson AJ; Liang X; Blazar BR; Miller JS
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):23-34. PubMed ID: 15625541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.